Schizophrenia Clinical Trials in Dallas, Texas

6 studies are recruiting for schizophrenia in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

   The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Local Institution - 0194, Dallas, Texas

   Locations

   59 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07686263 on ClinicalTrials.gov

2. A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

   The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   Local Institution - 0149, Dallas, Texas

   Locations

   91 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07424404 on ClinicalTrials.gov

3. Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

   The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

   Stage

   Not phased

   Ages

   18 and older

   Site

   Local Institution - 0050, Dallas, Texas

   Locations

   55 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07379827 on ClinicalTrials.gov

4. CLOZAPINE Response in Biotype-1

   The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as ps…

   Stage

   Phase 4

   Ages

   18 to 60

   Site

   UT Southwestern Medical Center, Dallas, Texas

   Locations

   5 in total

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT04580134 on ClinicalTrials.gov

5. Database Registry for Neural Network Biomarkers in Psychosis

   Several observations have been made with magnetic resonance imaging (MRI) that characterize brain connections and brain function in individuals with schizophrenia and other mental disorders. For example, research investigating schizophrenia focuses on the dysfunction of connections within and betwe…

   Stage

   Not phased

   Ages

   18 to 60

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT01409109 on ClinicalTrials.gov

6. Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

   The Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS) study aims to understand the early stages of psychotic disorders like Schizophrenia, Schizoaffective Disorder, and Bipolar I Disorder. It involves gathering mental health information, brain scans (MRI), eye movement …

   Stage

   Not phased

   Ages

   18 to 40

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Locations

   6 in total

   Run by

   Beth Israel Deaconess Medical Center

   See if you can join NCT06740383 on ClinicalTrials.gov